Acquired hemophilia A
Conditions
Interventions
None listed
Sponsors
Chugai Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Emi cohort inclusion criteria Patients who meet all of the following criteria will be included in the study. 1)Patients who have been given a claim injury/disease name of acquired hemophilia A 2)Patients for whom the health insurance claim for hospitalization has a health insurance claim name of acquired hemophilia A 3)Patients with prescription data of emicizumab from hospital admission given a health insurance claim injury name Acquired haemophilia A to the day before the next Index Date, the last receipt date, or the last day of the period covered by this data, whichever comes earlier Non-Emi Cohort Enrollment Criteria Patients who meet all of the following criteria will be included in the study. 1)Patients who have been given a claim injury/disease name of acquired hemophilia A 2)Patients for whom the health insurance claim for hospitalization has a health insurance claim name of acquired hemophilia A 3)Patients with prescription data of immunosuppressants during hospitalization given a health insurance claim injury name acquired hemophilia A 4)Hospitalization for which a health insurance claim injury name acquired hemophilia A was given, for which data on FVIII activity test or FVIII inhibitor titer test were obtained at least twice before the last day of the target period
Exclusion criteria
Exclusion criteria: Emi Cohort Exclusion Criteria Patients with any of the following injury/disease name data will be excluded from the study. All data periods are included. 1)Patients who have been given a claim injury/disease name of antiphospholipid antibody syndrome 2)Patients who have been given a claim injury/disease name of lupus anticoagulant 3)Patients with a claim injury/disease name of acquired factor XIII deficiency 4)Patients with a health insurance claim injury/disease name of autoimmune acquired Von Willebrand's disease 5)Patients with a claim injury/disease name of acquired factor V deficiency 6)Patients with a claim injury/disease name of primary antiphospholipid antibody syndrome Non-Emi Cohort Exclusion Criteria In addition to the same exclusion criteria as those for the Emi cohort, cases where prescription data of emicizumab exist during the period from the Index Date to the day before the next Index Date, the date of occurrence of the last receipt, or the last date of the period covered by this data, whichever comes earlier, will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current treatment status in patients with emicizumab Actual use status of emicizumab, immunosuppressants, hemostatic agents and blood transfusions, rehabilitation, and duration of hospitalization Clinical outcomes in patients with emicizumab ADL (activities of daily living) at discharge, haemorrhage | — |
Secondary
| Measure | Time frame |
|---|---|
| Current treatment status in patients without emicizumab Actual use status of immunosuppressants, hemostatic agents and blood transfusions, rehabilitation, and duration of hospitalization Clinical outcomes in patients without emicizumab ADL (activities of daily living) at discharge, haemorrhage Other clinical outcomes in patients with or without emicizumab Presence and time of onset of infection and thromboembolism, level of nursing care need after discharge and ADL (activities of daily living of nursing certified information in LTC-DB) and its changes from before hospitalization, recurrence of AHA, place of discharge, presence of dysphagia at admission, discharge and after discharge, presence of pressure sore at admission, discharge and after discharge, bleeding free survival time Medical expenses (drug expenses for treatment of acquired hemophilia A [bleed control/hemostatic drugs]) | — |
Countries
Japan
Contacts
Public ContactAyumu Matsuoka
NTT DATA Japan Corporation Healthcare Division
Outcome results
None listed